Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new £115 million biomedical research centre will pave the way for treatments for some of the biggest population health issues around the globe, potentially improving the everyday lives of millions.

Li Ka Shing Centre Opening May 2017

Opened with the support of a £20m gift from the Li Ka Shing Foundation, the centre will bring together researchers from related teams to analyse biomedical data from hundreds of thousands of people worldwide, speeding up both our understanding of diseases and the development of new treatments for conditions including cancer, Alzheimer’s and a number of infectious diseases.

The Li Ka Shing Centre for Health Information and Discovery incorporates two related research institutes at the heart of Oxford University's major biomedical campus in Headington. The two research institutes, the Target Discovery Institute (TDI) and the Big Data Institute (BDI), will lead the development of new types of research activity in the University.

Read more

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.